🇺🇸 FDA
Patent

US 10849875

Cancer specific lipid targeted peptidomimetics

granted A61KA61K31/337A61K31/343

Quick answer

US patent 10849875 (Cancer specific lipid targeted peptidomimetics) held by The Board of Regents of the University of Texas System expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/337, A61K31/343, A61K38/00, A61K47/55